申请人:HANMI PHARM. CO., LTD.
公开号:US20150299185A1
公开(公告)日:2015-10-22
Provided is a novel imidazopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.
提供了一种新型咪唑吡啶衍生物,具有不可逆的酪氨酸激酶抑制活性,以及包含该衍生物的药物组合物,可用于预防或治疗炎症性疾病、自身免疫性疾病、增生性疾病或过度增生性疾病、免疫介导性疾病、癌症或肿瘤。